Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?

Cathie Wood Just Bet Big on This Biotech Stock

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.

Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Growth Stocks With Highest Upside Potential. On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares. On July 9, Raymond James raised the firm’s price target […]

Morgan Stanley Raises its Price Target on Alnylam (ALNY)

IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.

Ionis Begins Dosing in Phase I/II Dravet Syndrome Study

Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.

Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?

A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua failed to meet the primary goal of a late-stage trial. The ...

Panic grips Ionis Pharmaceuticals investors amid bad news spree

Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after shares moved sharply higher, helped by the late stage failure of a competing ATTR cardiomyopathy therapy from AstraZeneca and Ionis Pharmaceuticals, as well as recent collaboration updates. See our latest analysis for Alnylam Pharmaceuticals. Even after the recent surge following competitor trial setbacks and collaboration news, Alnylam Pharmaceuticals’ 1-day share price return declined 4.49%, capping a year to date share price...

Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?

A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.

Insider Name	Relation to Company	Shares Changed	Price	Transaction Date
BAROLDI JOSEPH	Officer	5,635	$0.45	Jun 26, 2026
SCHNEIDER EUGENE	Officer	26,000	$2.11	Jun 26, 2026
O'NEIL PATRICK R	General Counsel	3,069	$0.25	Jun 26, 2026
MONIA BRETT P	Chief Executive Officer	85,637	$6.83	Jun 26, 2026
SWAYZE ERIC E	Officer	10,602	$0.84	Jun 25, 2026
BERTHELSEN SPENCER R	Director	8,000	$0.59	Jun 15, 2026
KORDASIEWICZ HOLLY B	Officer	60,846	$4.47	Jun 12, 2026
BERTHELSEN SPENCER R	Director	8,000	$0.20	Jun 1, 2026
MONIA BRETT P	Chief Executive Officer	4,536	$0.15	May 14, 2026
LOSCALZO JOSEPH	Director	77,289	$3.77	May 4, 2026

IONS(IONS)
NASDAQ

Company Profile & Information

Company Profile

Business Overview

Insider Transactions

Similar Companies

Analysis Tools

IONS(IONS)NASDAQ